The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

Einsele, Hermann; Borghaei, Hossein; Z. Orlowski, Robert; Subklewe, Marion; J. Roboz, Gail; Zugmaier, Gerhard; Kufer, Peter; Iskander, Karim; M. Kantarjian, Hagop

doi:10.1002/cncr.32909

Public

The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

Published in Cancer • May 13, 2020

Authors:

Hermann Einsele

Hossein Borghaei

Robert Z. Orlowski

Abstract

Immuno‐oncology therapies engage the immune system to treat cancer. BiTE (bispecific T‐cell engager) technology is a targeted immuno‐oncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation of molecules against tumor‐s...

View

Open Access

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!